What is the clinical evidence from this study?

Study design: Review. Population: Alzheimer's disease and related dementias. Intervention: Lipoproteins and CETP inhibitors.

What question did this study set out to answer?

Synthesize recent evidence on how lipoproteins influence Alzheimer's disease and related dementias, and evaluate emerging lipid-modifying therapeutic strategies targeting cholesteryl ester transfer protein.

September 28, 2026Molecular NeurodegenerationOpen Access

From mechanism to intervention: lipoproteins and Alzheimer’s disease

View Full Paper

Ask AI

Bookmark

Key result

CETP inhibitors show potential to slow plasma p-tau-217 progression in Alzheimer's disease.

Design

Review

Authors

TPTetiana PoliakovaUniversity of British Columbia LZLizi ZhangUniversity of British Columbia CWCheryl L. WellingtonUniversity of British Columbia

Discussion

Member takes

Implication

This review highlights the potential of targeting lipoprotein metabolism, specifically via CETP inhibition, as a therapeutic strategy for Alzheimer's disease and related dementias.

Key Points

Synthesize recent evidence on how lipoproteins influence Alzheimer's disease and related dementias, and evaluate emerging lipid-modifying therapeutic strategies targeting cholesteryl ester transfer protein.
Reviewed literature published between 2024 and 2026 addressing apolipoprotein E (ApoE), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in dementia.
Examined mechanistic links connecting midlife cardiovascular dyslipidemia to vascular contributions to cognitive impairment and dementia (VCID).
Evaluated clinical findings on cholesteryl ester transfer protein (CETP) modulation, focusing on 12-month outcomes of the CETP inhibitor obicetrapib in patients with atherosclerotic cardiovascular disease.
Cardiovascular risk factors, including dyslipidemia and hypertension, act as major modifiable drivers linking vascular cognitive impairment with amyloid and tau pathology.
The CETP inhibitor obicetrapib significantly slowed the accumulation of plasma p-tau-217, an approved biomarker of amyloid positivity, over 12 months in patients with atherosclerotic cardiovascular disease.
Protective biomarker effects of CETP inhibition on p-tau-217 progression were markedly more pronounced among individuals carrying the APOE4 allele.

PICO

Population

Alzheimer's disease and related dementias

Exposure / Comparator

Lipoproteins and CETP inhibitors

This review highlights the potential of targeting lipoprotein metabolism, specifically via CETP inhibition, as a therapeutic strategy for Alzheimer's disease and related dementias.

Cite This Study

Poliakova et al. (2026) conducted a review in Alzheimer's disease and related dementias. Lipoproteins and CETP inhibitors was evaluated. This narrative review highlights the role of lipoproteins in Alzheimer's disease and identifies CETP inhibitors like obicetrapib as potential therapies to slow plasma p-tau-217 progression.

synapsesocial.com/papers/6ab9b6277822ec8fc3d91c71 https://doi.org/10.1186/s13024-026-00993-7

View Full Paper

Ask AI

Bookmark

Implication

This review highlights the potential of targeting lipoprotein metabolism, specifically via CETP inhibition, as a therapeutic strategy for Alzheimer's disease and related dementias.

From mechanism to intervention: lipoproteins and Alzheimer’s disease

Discussion

Member takes

Implication

Key Points

PICO

Cite This Study

From mechanism to intervention: lipoproteins and Alzheimer’s disease

Discussion

Member takes

Implication

Key Points

PICO

Cite This Study

Also Consider

Also Consider